SEC Tracker
Get the app
SNOA · XBRL financial data

Sonoma Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (SNOA's year ends in late March)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024†Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue2,7313,1383,439*3,3913,5793,5643,754*4,0155,6044,3495,561*6,406
Revenue from contracts with customers2,7313,1383,439*3,3913,5793,5643,754*4,0155,6044,3495,561*6,406
Cost of revenue————2,2182,2942,226*2,5513,4842,6993,380*3,829
Cost of goods and services sold1,7411,6782,348*2,0852,2182,2942,226*2,551————
Gross profit9901,4601,091*1,3061,3611,2701,528*1,4642,1201,6502,181*2,577
Research and development536601409*470506427411*594575557545*597
Selling, general and administrative1,6621,7032,091*2,0091,7051,8741,773*1,9651,8821,7711,987*2,020
Total operating expenses2,1982,3042,500*2,4792,2112,3012,184*2,5592,4572,3282,532*2,617
Other operating income (expense)(90)(79)50*176387112128*(147)(394)(271)(146)*(290)
Operating income (loss)(1,208)(844)(1,409)*(1,173)(850)(1,031)(656)*(1,095)(337)(678)(351)*(40)
Income tax expense (benefit)186(57)(292)*1461479248*(1)(197)(130)84*0
Net income (loss)(1,484)(866)(1,067)*(1,143)(610)(928)(776)*(1,241)(534)(819)(581)*(330)
Earnings per share, basic USD per share(0.29)(0.08)—(0.07)(0.59)(0.63)—(0.76)(0.32)(0.48)(0.33)*(0.09)
Earnings per share, diluted USD per share(0.29)(0.08)—(0.07)(0.59)(0.63)—(0.76)(0.32)(0.48)(0.33)*(0.09)
Weighted average shares, basic thousands of shares510,909—17,0291,0341,464—1,6411,6461,7131,737*3,846
Weighted average shares, diluted thousands of shares510,909—17,0291,0341,464—1,6411,6461,7131,737*3,846
  • † Share count changed about 1/14 in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (SNOA's year ends in late March)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024†Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents2,1372,4063,1282,5894,0785,2365,3743,6053,0352,5612,3995,338
Accounts receivable2,2232,8762,8983,2473,1572,4052,2322,6022,7032,3822,5273,182
Inventory2,5132,9552,7192,6582,8373,1432,9153,8023,6343,7033,6513,786
Prepaid and other current assets4,3954,0093,5413,1961,9291,3871,9152,8682,9253,3513,4363,962
Total current assets11,51612,50212,54811,92712,22112,38012,64813,10712,50112,14512,10016,268
Property and equipment, net433397365302255215225301284314310290
Right-of-use asset35034128621616211984536479642602578
Total assets13,63514,61814,74013,67313,68513,66813,69314,59413,85613,62313,96018,107
Accounts payable9878646077517701,3959532,0461,4041,6461,9232,191
Total current liabilities3,2393,0743,7193,7513,3093,7034,0964,8484,3224,2174,8325,447
Lease liability, non-current1341608761462927440391509469439
Total liabilities7,9607,9268,6038,6988,3338,7989,28210,53810,06910,19110,86511,513
Accumulated deficit(192,416)(193,282)(194,349)(195,492)(196,102)(197,030)(197,806)(199,047)(199,581)(200,400)(200,981)(201,311)
Total stockholders' equity5,6756,6926,1374,9755,3524,8704,4114,0563,7873,4323,0956,594
Total liabilities and equity13,63514,61814,74013,67313,68513,66813,69314,59413,85613,62313,96018,107
Common shares outstanding (cover page) thousands of shares13,67915,60718,77419,1491,3391,6161,6431,6431,7011,7314,7864,788
  • † Share count changed about 1/14 in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (SNOA's year ends in late March)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024†Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(1,484)(866)(1,067)*(1,143)(610)(928)(776)*(1,241)(534)(819)(581)*(330)
Stock-based compensation13014069*107141390*573924135*58
Depreciation and amortization45*45*41*3935*33*—3636*34*—32
Net cash from operating activities(1,231)*(1,104)*152*(912)354*565*(95)*(2,015)(635)*(764)*(519)*(649)
Purchases of property and equipment2*1*(3)*526*2*47*10610*47*29*2
Net cash from investing activities(2)*(1)*18*(5)(26)*(2)*(47)*(106)(10)*(47)*(29)*(2)
Proceeds from issuing common stock0*1,451*338*7481,541*790*0*00*266*161*3,536
Net cash from financing activities(129)*1,318*622*6361,444*708*242*(58)(62)*210*387*3,454
Net change in cash(1,407)*269*722*(539)1,489*1,158*138*(1,769)(570)*(474)*(162)*2,939
  • † Share count changed about 1/14 in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Sonoma Pharmaceuticals5,3386,406(649)4.8M8.2 quarters 10-QJun 30, 2026
Autonomix Medical3,4600(3,544)971,0431.0 quarters 10-QJun 30, 2026
Odyssey Health122not reported(160)*110.2M0.8 quarters 10-KJul 31, 2026
Family Office of America637533149*30.8M— 10-QJun 30, 2026
Adm Tronics Unlimited223not reported(33)67.6M6.8 quarters 10-QJun 30, 2026
Aethlon Medical4,934not reported(1,897)711,1362.6 quarters 10-QJun 30, 2026
Bone Biologics6,088not reported(532)*3.4M9.8 quarters 10-QSep 30, 2026
SeaStar Medical Holding6,959615(2,994)*4.4M2.3 quarters 10-QJun 30, 2026
ENvue Medical1,084239(2,691)*11.1M0.4 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.